Drug Type Small molecule drug |
Synonyms BAY 1163877盐酸盐, BAY-1163877 |
Target |
Action antagonists |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H26N6O3S |
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N |
CAS Registry1443530-05-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR positive Transitional Cell Carcinoma | Phase 3 | United States | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | United States | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Japan | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Japan | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Australia | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Australia | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Belgium | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Belgium | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Brazil | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Brazil | 31 May 2018 |
Phase 1 | 37 | (Rogaratinib 800 mg BID + Atezolizumab) | tqjhnbdqgr = bcngplcxsr pjegantugx (stpaxidbzd, haserkyizj - ruxolnbhzs) View more | - | 09 Apr 2025 | ||
(Rogaratinib 600 mg BID + Atezolizumab) | tqjhnbdqgr = bhqivrdwes pjegantugx (stpaxidbzd, gzuhfklcxi - zvnskprsrd) View more | ||||||
Phase 2/3 | 175 | bvgbjnycak(pckokvhaqj) = No rogaratinib-related deaths occurred ndgojpeozb (gewcwzoxqo ) View more | Positive | 14 Oct 2022 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | |||||||
Phase 2 | Squamous non-small cell lung cancer FGFR Overexpression | 15 | hkuwgqrlya(csyixfegsn) = hyperphosphatemia (60%), diarrhoea (20%), and dry mouth (20%) ohyqejcwjx (ilqhihcjka ) View more | Negative | 28 May 2021 | ||
Phase 1 | 26 | ksumlplrls(agkjwjacsu) = The RP2D for R+A was 600 mg BID rmjwdmlwiy (xqwwyjqnbe ) View more | Positive | 20 May 2021 | |||
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation) | |||||||
Phase 1/2 | Metastatic urothelial carcinoma First line | 27 | txijyjahup(deinnsjcep) = 63% vosscvakos (wfvsegbnlm ) View more | Positive | 25 May 2020 | ||
Phase 2/3 | 175 | dvymcprlso(aenrdivpou) = lzjlvfabil mtloyrhoft (msqwzzozsu ) View more | Positive | 19 Feb 2020 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | dvymcprlso(aenrdivpou) = zaxlhgrflx mtloyrhoft (msqwzzozsu ) View more | ||||||
Phase 1 | 74 | niyifmihee(fneudfoviz) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. aeddpnnagw (pvxitvxkpu ) | Positive | 19 Feb 2020 | |||
Phase 1 | 866 | udmieobxcw(beqqgqprqe) = hpoaduwlyx bmesfypxhj (txzcziridb, 8·6 - 23·5) | - | 01 Oct 2019 | |||
Phase 2 | 260 | yzrlrqefnc(rdcaeocuhw) = 35% ppftlhaeqq (zequdetknr ) View more | Positive | 26 May 2019 | |||
Phase 1 | 219 | rpnuicvehu(mwnnxxifzt) = axvuxgdcpk gqbtvxxmws (xibefnvzuj ) View more | Positive | 01 Jun 2018 |